Downstaging and Histological Effects Might Be Reliable Predictors of the Efficacy of DOC+CDDP+5-FU (DCF) as Neoadjuvant Therapy for Stage III or Borderline Resectable Esophageal Cancer: a Single Institute Experience.
Kobayashi K, Kanetaka K, Yoneda A, Kobayashi S, Maruya Y, Isagawa Y, Yoshimoto T, Migita K, Kawaguchi Y, Kuba S, Morita M, Okada S, Kosaka T, Yamaguchi S, Inoue Y, Adachi T, Hidaka M, Torashima Y, Ito S, Takatsuki M, Eguchi S.
Kobayashi K, et al. Among authors: isagawa y.
J Gastrointest Cancer. 2021 Jun;52(2):582-592. doi: 10.1007/s12029-020-00431-x.
J Gastrointest Cancer. 2021.
PMID: 32524305